163 related articles for article (PubMed ID: 21913193)
1. Axillary reverse mapping using a fluorescence imaging system in breast cancer.
Noguchi M; Noguchi M; Nakano Y; Ohno Y; Kosaka T
J Surg Oncol; 2012 Mar; 105(3):229-34. PubMed ID: 21913193
[TBL] [Abstract][Full Text] [Related]
2. Axillary reverse mapping with indocyanine fluorescence imaging in patients with breast cancer.
Noguchi M; Yokoi M; Nakano Y
J Surg Oncol; 2010 Mar; 101(3):217-21. PubMed ID: 20063370
[TBL] [Abstract][Full Text] [Related]
3. High rate of solitary sentinel node metastases identification by fluorescence-guided lymphatic imaging in breast cancer.
Hirche C; Mohr Z; Kneif S; Murawa D; Hünerbein M
J Surg Oncol; 2012 Feb; 105(2):162-6. PubMed ID: 21882198
[TBL] [Abstract][Full Text] [Related]
4. The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer.
Fan YG; Tan YY; Wu CT; Treseler P; Lu Y; Chan CW; Hwang S; Ewing C; Esserman L; Morita E; Leong SP
Ann Surg Oncol; 2005 Sep; 12(9):705-11. PubMed ID: 16079953
[TBL] [Abstract][Full Text] [Related]
5. Sentinel node mapping for breast cancer: the operative experience of a breast surgeon in a rural community.
Davit FE; Gatmaitan P; Garguilo G
Am Surg; 2008 May; 74(5):423-7. PubMed ID: 18481500
[TBL] [Abstract][Full Text] [Related]
6. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H
Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
[TBL] [Abstract][Full Text] [Related]
7. Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND.
Goyal A; Newcombe RG; Chhabra A; Mansel RE
Ann Surg Oncol; 2008 Jan; 15(1):262-7. PubMed ID: 17879117
[TBL] [Abstract][Full Text] [Related]
8. Feasibility study of axillary reverse mapping for patients with clinically node-negative breast cancer.
Noguchi M; Noguchi M; Ohno Y; Morioka E; Nakano Y; Kosaka T; Kurose N; Minato H
Eur J Surg Oncol; 2016 May; 42(5):650-6. PubMed ID: 27005806
[TBL] [Abstract][Full Text] [Related]
9. Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence.
Murawa D; Hirche C; Dresel S; Hünerbein M
Br J Surg; 2009 Nov; 96(11):1289-94. PubMed ID: 19847873
[TBL] [Abstract][Full Text] [Related]
10. Is axillary reverse mapping feasible in breast cancer patients?
Noguchi M; Miura S; Morioka E; Ohno Y; Yokoi-Noguchi M; Nakano Y; Kosaka T
Eur J Surg Oncol; 2015 Apr; 41(4):442-9. PubMed ID: 25704555
[TBL] [Abstract][Full Text] [Related]
11. Predicting the likelihood of additional nodal metastases in breast carcinoma patients with positive sentinel node biopsy.
Mustać E; Matusan-Ilijas K; Marijić B; Smokvina M; Jonjić N
Int J Surg Pathol; 2010 Feb; 18(1):36-41. PubMed ID: 19448065
[TBL] [Abstract][Full Text] [Related]
12. Axillary reverse mapping: mapping and preserving arm lymphatics may be important in preventing lymphedema during sentinel lymph node biopsy.
Boneti C; Korourian S; Bland K; Cox K; Adkins LL; Henry-Tillman RS; Klimberg VS
J Am Coll Surg; 2008 May; 206(5):1038-42; discussion 1042-4. PubMed ID: 18471751
[TBL] [Abstract][Full Text] [Related]
13. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.
Reitsamer R; Peintinger F; Rettenbacher L; Prokop E
J Surg Oncol; 2003 Oct; 84(2):63-7. PubMed ID: 14502778
[TBL] [Abstract][Full Text] [Related]
14. Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly related to patient age and tumor size: a new source of bias in morbidity assessment?
Port ER; Patil S; Stempel M; Morrow M; Cody HS
Cancer; 2010 Apr; 116(8):1987-91. PubMed ID: 20151427
[TBL] [Abstract][Full Text] [Related]
15. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study.
Langer I; Guller U; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
Ann Surg Oncol; 2009 Dec; 16(12):3366-74. PubMed ID: 19760047
[TBL] [Abstract][Full Text] [Related]
16. Intraoperative evaluation of sentinel lymph nodes in invasive lobular carcinoma of the breast.
Taras AR; Hendrickson NA; Pugliese MS; Lowe KA; Atwood M; Beatty JD
Am J Surg; 2009 May; 197(5):643-6; discussion 646-7. PubMed ID: 19393357
[TBL] [Abstract][Full Text] [Related]
17. Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy?
Specht MC; Fey JV; Borgen PI; Cody HS
J Am Coll Surg; 2005 Jan; 200(1):10-4. PubMed ID: 15631914
[TBL] [Abstract][Full Text] [Related]
18. Axillary lymph node dissection in the case of sentinel lymph node micrometastatic invasion: evaluation of three predictive models.
Orsoni M; Clerc J; Golfier F; Cortet M; Raudrant D; Krauth JS
Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):334-7. PubMed ID: 21669485
[TBL] [Abstract][Full Text] [Related]
19. Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients.
Langer I; Guller U; Hsu-Schmitz SF; Ladewig A; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
Eur J Surg Oncol; 2009 Aug; 35(8):805-13. PubMed ID: 19046846
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
Shen J; Gilcrease MZ; Babiera GV; Ross MI; Meric-Bernstam F; Feig BW; Kuerer HM; Francis A; Ames FC; Hunt KK
Cancer; 2007 Apr; 109(7):1255-63. PubMed ID: 17330229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
